基因型鑒定檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按產品/服務、技術、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球基因型鑒定檢測市場預計將從 2025 年的 178.9 億美元成長到 2031 年的 416.4 億美元，複合年成長率達 15.12%，呈現強勁成長動能。

基因型鑒定檢測是一種透過將DNA序列與參考序列進行比較來識別生物體特定基因組成的分析方法，由於藥物基因體學的應用日益廣泛以及需要標靶治療的遺傳疾病在全球範圍內發病率不斷上升，基因分型檢測的需求量很大。近期行業數據也支持了這種向精準醫療的轉變。根據個人化醫療聯盟（Personalized Medicine Coalition）發布的「2025年」預測，去年共有18種新的個人化藥物獲得核准，約佔新核准治療性分子實體總數的38%。

另一方面，市場發展面臨一個重大障礙：診斷檢測監管框架日益複雜。特別是，對實驗室自建檢測（LDT）的監管日益嚴格，合規要求不斷變化，這對臨床檢查室和生產商而言都是巨大的挑戰。這種監管的不確定性會成為營運負擔，延緩創新檢測方法的推出，並增加研發成本，從而有效地限制了基因分型解決方案在全球的快速普及。

市場促進因素

高通量定序和PCR技術的突破正在從根本上改變基因型鑒定格局，使檢查室能夠以前所未有的速度和精度處理海量基因資料庫。次世代定序平台現在可以同時分析多個基因組區域，降低單一樣本的成本，並提高大規模人口研究的擴充性。這項轉變得益於先進儀器的快速普及。根據Illumina公司於2024年2月發布的“2023會計年度第四季度及全年業績報告”，該公司報告稱，上一會計年度共交付了352台NovaSeq X測序儀，這凸顯了行業正朝著高容量基因組基礎設施的方向發展，以確保從基礎研究到複雜診斷等各項服務的複雜性診斷。

同時，隨著慢性病和遺傳性疾病在全球日益普遍，基因型鑒定被擴大整合到常規臨床工作流程和藥物研發流程中。隨著癌症等疾病負擔的加重，醫療服務提供者越來越依賴基因組分析來識別生物標記和進行早期檢測。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》，預計2024年美國新增癌症病例將達到2,001,140例，這使得精準的診斷工具變得尤為迫切。為了滿足由此產生的運算需求，生物銀行和生物資訊學領域正獲得大量投資。例如，諾和諾德基金會承諾在2024年投入約6億丹麥克朗，用於建造一台最先進的人工智慧超級電腦，以加速生命科學研究。

市場挑戰

全球基因分型檢測市場的擴張正受到診斷檢測領域複雜法規環境的顯著阻礙，尤其是實驗室自建檢測（LDT）監管力度的加強。將這些檢測歸類為醫療設備意味著執法自由裁量權的終結，迫使臨床檢查室必須應對嚴格的上市前審查並遵守品質系統要求。這項轉變立即帶來營運挑戰，迫使檢查室將資金和技術專長從創新基因型鑒定檢測轉移到確保現有庫存水準的行政合規性。

這些監管壁壘的規模直接限制了市場擴充性，造成檢測交付瓶頸並推高了研發成本。大量需要追溯核准的檢測項目給資源帶來了沉重負擔。例如，根據美國醫院協會2024年的報告，一家大型醫療機構報告稱，其管理的現有實驗室自建檢測（LDT）至少有1600項，根據新規，這些檢測都需要單獨提交監管申請。面對如此繁瑣的申請要求，檢查室預計將簡化其檢測項目並推遲推出先進的基因分型解決方案，有效抑制市場擴張。

市場趨勢

利用液態生物檢體進行基因分型的應用正在重塑市場格局，它能夠實現非侵入性、即時的疾病監測，克服了傳統組織取樣的限制。這一趨勢在精準腫瘤學領域尤為明顯。液態生物檢體可以對循環腫瘤DNA進行時間序列分析，從而識別新出現的抗藥性突變並動態調整治療策略。越來越多的臨床檢驗支持了這項能力。為了展示其效用，Guardant Health公司在2025年6月發布的新聞稿《SERENA-6 III期試驗證實Guardant360 CDx檢測的臨床價值》中報告稱，使用其液態生物檢體檢測方法檢測新出現的ESR1突變並調整治療方案，可使進行性乳癌患者的疾病進展或死亡風險降低56%。

同時，數位PCR技術在精確定量方面的日益普及正在推動市場成長。這是因為檢查室需要超越定量PCR靈敏度的絕對核酸測量能力。這項技術對於檢測病毒量監測、細胞和基因療法品管等領域的稀有標靶至關重要，且無需參考物質。製造商正在擴展產品線以滿足這一需求。根據Bio-Rad Laboratories, Inc.於2025年7月發布的題為「Bio-Rad擴展液滴數位PCR產品供應」的新聞稿，該公司目前提供超過40萬種檢測方法，顯著擴大了臨床診斷和生命科學研究領域高精度數位PCR解決方案的覆蓋範圍。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球基因型鑒定檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品/服務分類（試劑/試劑盒、基因型鑒定服務、儀器、定序儀/擴增儀、分析儀器、生物資訊、軟體、服務）
  • 透過技術（PCR（即時PCR、數位PCR）、微陣列、定序（NGS、焦磷酸測序、Sanger定序）、毛細管電泳（擴增片段長度多態性、限制性內切酶片段長度多態性、單鏈構像多態性）、MALDI-TOF、其他）
  • 依應用領域（藥物基因體學、診斷與個人化醫療、農業生物技術、動物遺傳學及其他應用）
  • 按最終用戶（製藥和生物製藥公司、診斷和研究實驗室、學術機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美基因型鑒定檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲基因基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲基因基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球基因型鑒定檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Qiagen NV
• Agilent Technologies Inc.
• Danaher Corporation
• Hoffmann-La Roche Ltd.
• GE HealthCare Technologies Inc.
• Standard BioTools Inc.
• Eurofins Scientific SE
• Bio-Rad Laboratories Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Genotyping Assay Market is projected to experience robust growth, expanding from USD 17.89 Billion in 2025 to USD 41.64 Billion by 2031, representing a CAGR of 15.12%. Genotyping assays, which are analytical solutions used to ascertain an organism's specific genetic makeup by comparing DNA sequences to a reference standard, are seeing increased demand due to the broader application of pharmacogenomics and the rising global incidence of genetic diseases requiring targeted therapies. This transition toward precision healthcare is supported by recent industry data; according to the 'Personalized Medicine Coalition' in '2025', 18 new personalized medicines were approved in the preceding year, making up approximately 38 percent of all newly approved therapeutic molecular entities.

Conversely, market progress faces a significant obstacle in the form of an increasingly complex regulatory framework governing diagnostic testing. In particular, tighter oversight and evolving compliance mandates regarding Laboratory Developed Tests create substantial hurdles for clinical laboratories and manufacturers. These regulatory uncertainties impose operational burdens that can delay the launch of innovative assays and increase development costs, thereby effectively constraining the rapid global scalability of genotyping solutions.

Market Driver

Technological breakthroughs in high-throughput sequencing and PCR are fundamentally transforming the genotyping landscape, enabling laboratories to process extensive genetic data libraries with unmatched speed and accuracy. Next-generation sequencing platforms now facilitate the simultaneous analysis of multiple genomic regions, reducing per-sample costs and improving scalability for large-scale population studies, a shift evidenced by the rapid adoption of advanced instrumentation. According to Illumina Inc., February 2024, in the 'Fourth Quarter and Full Year 2023 Financial Results', the company reported shipping 352 NovaSeq X instruments during the prior fiscal year, highlighting the industrial move toward high-capacity genomic infrastructure that ensures services remain accessible for applications ranging from basic research to complex diagnostics.

Simultaneously, the escalating global prevalence of chronic diseases and genetic disorders is driving the integration of genotyping into routine clinical workflows and drug discovery pipelines. As the burden of pathologies like cancer grows, healthcare providers increasingly depend on genomic profiling for biomarker identification and early detection; according to the American Cancer Society, January 2024, in 'Cancer Facts & Figures 2024', 2,001,140 new cancer cases are projected in the United States in 2024, creating an urgent need for precise diagnostic tools. To handle the resulting computational demands, substantial investments are targeting biobanking and informatics, such as the Novo Nordisk Foundation's 2024 commitment of approximately DKK 600 million to establish a state-of-the-art AI supercomputer to accelerate life sciences research.

Market Challenge

The expansion of the Global Genotyping Assay Market is notably impeded by the intricate regulatory environment surrounding diagnostic testing, particularly regarding the stricter oversight of Laboratory Developed Tests (LDTs). The shift to classify these tests as medical devices marks the end of enforcement discretion, compelling clinical laboratories to navigate rigorous premarket reviews and adhere to quality system mandates. This transition creates immediate operational challenges, forcing laboratories to divert capital and technical expertise away from innovating new genotyping assays and toward ensuring administrative compliance for their current inventories.

The scale of these regulatory hurdles directly limits market scalability by creating bottlenecks in test availability and driving up development costs. The sheer volume of assays requiring retroactive approval places a massive strain on resources; for instance, according to the 'American Hospital Association' in '2024', one major health system reported managing at least 1,600 existing Laboratory Developed Tests that would necessitate individual regulatory submissions under the new rules. Faced with such extensive filing requirements, laboratories are expected to streamline their test menus and postpone the introduction of advanced genotyping solutions, effectively stalling market expansion.

Market Trends

The rise of liquid biopsy genotyping applications is reshaping the market by facilitating non-invasive, real-time disease monitoring that bypasses the limitations of traditional tissue sampling. This trend is especially significant in precision oncology, where liquid biopsies enable the longitudinal analysis of circulating tumor DNA to identify emerging resistance mutations and guide dynamic therapeutic adjustments, a capability supported by growing clinical validation. Demonstrating this utility, according to Guardant Health, Inc., June 2025, in the 'SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test' press release, using the company's liquid biopsy assay to detect emerging ESR1 mutations and switch therapies reduced the risk of disease progression or death by 56 percent in advanced breast cancer patients.

Concurrently, the growing adoption of digital PCR for precision quantification is propelling market growth as laboratories seek absolute nucleic acid measurement capabilities that exceed the sensitivity of quantitative PCR. This technology is becoming indispensable for detecting rare targets, such as in viral load monitoring and cell and gene therapy quality control, without requiring reference standards. Manufacturers are expanding their portfolios to meet this demand; according to Bio-Rad Laboratories, Inc., July 2025, in the 'Bio-Rad Expands Droplet Digital PCR Offering' press release, the company now offers more than 400,000 assays, significantly widening access to high-precision digital PCR solutions for clinical diagnostics and life science research.

Key Market Players

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Qiagen NV
• Agilent Technologies Inc.
• Danaher Corporation
• Hoffmann-La Roche Ltd.
• GE HealthCare Technologies Inc.
• Standard BioTools Inc.
• Eurofins Scientific SE
• Bio-Rad Laboratories Inc.

Report Scope

In this report, the Global Genotyping Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genotyping Assay Market, By Product & Service

• Reagents & Kits
• Genotyping Services
• Instruments
• Sequencers & Amplifiers
• Analyzers
• Bioinformatics
• Software
• Services

Genotyping Assay Market, By Technology

• PCR (Real-time PCR Digital PCR)
• Microarrays
• Sequencing
• Capillary Electrophoresis
• MALDI-TOF
• Others

Genotyping Assay Market, By Application

• Pharmacogenomics
• Diagnostic & Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Other Applications

Genotyping Assay Market, By End User

• Pharmaceutical and Biopharmaceutical Companies
• Diagnostic and Research Laboratories
• Academic Institutes
• Others

Genotyping Assay Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genotyping Assay Market.

Available Customizations:

Global Genotyping Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genotyping Assay Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Reagents & Kits, Genotyping Services, Instruments, Sequencers & Amplifiers, Analyzers, Bioinformatics, Software, Services)
  • 5.2.2. By Technology (PCR (Real-time PCR, Digital PCR), Microarrays, Sequencing (NGS, Pyrosequencing, Sanger Sequencing), Capillary Electrophoresis (Amplified Fragment Length Polymorphism, Restricted Fragment Length Polymorphism, Single-stranded Conformation Polymorphism), MALDI-TOF, Others)
  • 5.2.3. By Application (Pharmacogenomics, Diagnostic & Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Other Applications)
  • 5.2.4. By End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Genotyping Assay Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genotyping Assay Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Genotyping Assay Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Genotyping Assay Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Genotyping Assay Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genotyping Assay Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Genotyping Assay Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Genotyping Assay Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Genotyping Assay Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Genotyping Assay Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Genotyping Assay Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genotyping Assay Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Genotyping Assay Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Genotyping Assay Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Genotyping Assay Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Genotyping Assay Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Genotyping Assay Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genotyping Assay Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Genotyping Assay Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Genotyping Assay Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Genotyping Assay Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genotyping Assay Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Genotyping Assay Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Genotyping Assay Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genotyping Assay Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. Qiagen NV
• 15.4. Agilent Technologies Inc.
• 15.5. Danaher Corporation
• 15.6. Hoffmann-La Roche Ltd.
• 15.7. GE HealthCare Technologies Inc.
• 15.8. Standard BioTools Inc.
• 15.9. Eurofins Scientific SE
• 15.10. Bio-Rad Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer